Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study

Britton Trabert, Kara A. Michels, Garnet L. Anderson, Louise A. Brinton, Roni T. Falk, Ashley M. Geczik, Holly R. Harris, Kathy Pan, Ruth M. Pfeiffer, Lihong Qi, Thomas Rohan, Nicolas Wentzensen, Xia Xu

Research output: Contribution to journalArticle

Abstract

Our knowledge of epidemiologic risk factors for ovarian cancer supports a role for androgens in the pathogenesis of this disease; however, few studies have examined associations between circulating androgens and ovarian cancer risk. Using highly sensitive LC–MS/MS assays, we evaluated associations between pre-diagnostic serum levels of 12 androgens, including novel androgen metabolites that reflect androgen activity in tissues, and ovarian cancer risk among postmenopausal women in a nested case–control study in the Women's Health Initiative (WHI) Observational Study (OS). We frequency-matched 169 ovarian cancer cases to 410 controls from women enrolled in WHI-OS who were not using menopausal hormones at enrollment/blood draw. We estimated associations overall and by subtype (n = 102 serous/67 non-serous) using multivariable adjusted logistic regression. Androgen/androgen metabolite levels were not associated with overall ovarian cancer risk. In analyses by subtype, women with increased levels of androsterone-glucuronide (ADT-G) and total 5-α reduced glucuronide metabolites (markers of tissue-level androgenic activity) were at increased risk of developing non-serous ovarian cancer: ADT-G tertile (T)3 versus T1 odds ratio [OR] (95% confidence interval [CI]) 4.36 (1.68–11.32), p-heterogeneity 0.002; total glucuronide metabolites 3.63 (1.47–8.95), 0.002. Risk of developing serous tumors was unrelated to these markers. ADT-G and total glucuronide metabolites, better markers of tissue-level androgenic activity in women than testosterone, were associated with an increased risk of developing non-serous ovarian cancer. Our work demonstrates that sex steroid metabolism is important in the etiology of non-serous ovarian cancers and supports a heterogeneous hormonal etiology across histologic subtypes of ovarian cancer.

Original languageEnglish (US)
JournalInternational Journal of Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Women's Health
Ovarian Neoplasms
Androgens
Observational Studies
Glucuronides
Epidemiologic Factors
Testosterone
Logistic Models
Odds Ratio
Steroids
Hormones
Confidence Intervals
Serum

Keywords

  • androgen metabolites
  • androgenic activity
  • endogenous androgens
  • heterogeneity
  • nested case–control study
  • ovarian cancer risk

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study. / Trabert, Britton; Michels, Kara A.; Anderson, Garnet L.; Brinton, Louise A.; Falk, Roni T.; Geczik, Ashley M.; Harris, Holly R.; Pan, Kathy; Pfeiffer, Ruth M.; Qi, Lihong; Rohan, Thomas; Wentzensen, Nicolas; Xu, Xia.

In: International Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Trabert, B, Michels, KA, Anderson, GL, Brinton, LA, Falk, RT, Geczik, AM, Harris, HR, Pan, K, Pfeiffer, RM, Qi, L, Rohan, T, Wentzensen, N & Xu, X 2019, 'Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study', International Journal of Cancer. https://doi.org/10.1002/ijc.32157
Trabert, Britton ; Michels, Kara A. ; Anderson, Garnet L. ; Brinton, Louise A. ; Falk, Roni T. ; Geczik, Ashley M. ; Harris, Holly R. ; Pan, Kathy ; Pfeiffer, Ruth M. ; Qi, Lihong ; Rohan, Thomas ; Wentzensen, Nicolas ; Xu, Xia. / Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study. In: International Journal of Cancer. 2019.
@article{03649a0c3ef04816af72e5a39bb8d23e,
title = "Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study",
abstract = "Our knowledge of epidemiologic risk factors for ovarian cancer supports a role for androgens in the pathogenesis of this disease; however, few studies have examined associations between circulating androgens and ovarian cancer risk. Using highly sensitive LC–MS/MS assays, we evaluated associations between pre-diagnostic serum levels of 12 androgens, including novel androgen metabolites that reflect androgen activity in tissues, and ovarian cancer risk among postmenopausal women in a nested case–control study in the Women's Health Initiative (WHI) Observational Study (OS). We frequency-matched 169 ovarian cancer cases to 410 controls from women enrolled in WHI-OS who were not using menopausal hormones at enrollment/blood draw. We estimated associations overall and by subtype (n = 102 serous/67 non-serous) using multivariable adjusted logistic regression. Androgen/androgen metabolite levels were not associated with overall ovarian cancer risk. In analyses by subtype, women with increased levels of androsterone-glucuronide (ADT-G) and total 5-α reduced glucuronide metabolites (markers of tissue-level androgenic activity) were at increased risk of developing non-serous ovarian cancer: ADT-G tertile (T)3 versus T1 odds ratio [OR] (95{\%} confidence interval [CI]) 4.36 (1.68–11.32), p-heterogeneity 0.002; total glucuronide metabolites 3.63 (1.47–8.95), 0.002. Risk of developing serous tumors was unrelated to these markers. ADT-G and total glucuronide metabolites, better markers of tissue-level androgenic activity in women than testosterone, were associated with an increased risk of developing non-serous ovarian cancer. Our work demonstrates that sex steroid metabolism is important in the etiology of non-serous ovarian cancers and supports a heterogeneous hormonal etiology across histologic subtypes of ovarian cancer.",
keywords = "androgen metabolites, androgenic activity, endogenous androgens, heterogeneity, nested case–control study, ovarian cancer risk",
author = "Britton Trabert and Michels, {Kara A.} and Anderson, {Garnet L.} and Brinton, {Louise A.} and Falk, {Roni T.} and Geczik, {Ashley M.} and Harris, {Holly R.} and Kathy Pan and Pfeiffer, {Ruth M.} and Lihong Qi and Thomas Rohan and Nicolas Wentzensen and Xia Xu",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ijc.32157",
language = "English (US)",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study

AU - Trabert, Britton

AU - Michels, Kara A.

AU - Anderson, Garnet L.

AU - Brinton, Louise A.

AU - Falk, Roni T.

AU - Geczik, Ashley M.

AU - Harris, Holly R.

AU - Pan, Kathy

AU - Pfeiffer, Ruth M.

AU - Qi, Lihong

AU - Rohan, Thomas

AU - Wentzensen, Nicolas

AU - Xu, Xia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Our knowledge of epidemiologic risk factors for ovarian cancer supports a role for androgens in the pathogenesis of this disease; however, few studies have examined associations between circulating androgens and ovarian cancer risk. Using highly sensitive LC–MS/MS assays, we evaluated associations between pre-diagnostic serum levels of 12 androgens, including novel androgen metabolites that reflect androgen activity in tissues, and ovarian cancer risk among postmenopausal women in a nested case–control study in the Women's Health Initiative (WHI) Observational Study (OS). We frequency-matched 169 ovarian cancer cases to 410 controls from women enrolled in WHI-OS who were not using menopausal hormones at enrollment/blood draw. We estimated associations overall and by subtype (n = 102 serous/67 non-serous) using multivariable adjusted logistic regression. Androgen/androgen metabolite levels were not associated with overall ovarian cancer risk. In analyses by subtype, women with increased levels of androsterone-glucuronide (ADT-G) and total 5-α reduced glucuronide metabolites (markers of tissue-level androgenic activity) were at increased risk of developing non-serous ovarian cancer: ADT-G tertile (T)3 versus T1 odds ratio [OR] (95% confidence interval [CI]) 4.36 (1.68–11.32), p-heterogeneity 0.002; total glucuronide metabolites 3.63 (1.47–8.95), 0.002. Risk of developing serous tumors was unrelated to these markers. ADT-G and total glucuronide metabolites, better markers of tissue-level androgenic activity in women than testosterone, were associated with an increased risk of developing non-serous ovarian cancer. Our work demonstrates that sex steroid metabolism is important in the etiology of non-serous ovarian cancers and supports a heterogeneous hormonal etiology across histologic subtypes of ovarian cancer.

AB - Our knowledge of epidemiologic risk factors for ovarian cancer supports a role for androgens in the pathogenesis of this disease; however, few studies have examined associations between circulating androgens and ovarian cancer risk. Using highly sensitive LC–MS/MS assays, we evaluated associations between pre-diagnostic serum levels of 12 androgens, including novel androgen metabolites that reflect androgen activity in tissues, and ovarian cancer risk among postmenopausal women in a nested case–control study in the Women's Health Initiative (WHI) Observational Study (OS). We frequency-matched 169 ovarian cancer cases to 410 controls from women enrolled in WHI-OS who were not using menopausal hormones at enrollment/blood draw. We estimated associations overall and by subtype (n = 102 serous/67 non-serous) using multivariable adjusted logistic regression. Androgen/androgen metabolite levels were not associated with overall ovarian cancer risk. In analyses by subtype, women with increased levels of androsterone-glucuronide (ADT-G) and total 5-α reduced glucuronide metabolites (markers of tissue-level androgenic activity) were at increased risk of developing non-serous ovarian cancer: ADT-G tertile (T)3 versus T1 odds ratio [OR] (95% confidence interval [CI]) 4.36 (1.68–11.32), p-heterogeneity 0.002; total glucuronide metabolites 3.63 (1.47–8.95), 0.002. Risk of developing serous tumors was unrelated to these markers. ADT-G and total glucuronide metabolites, better markers of tissue-level androgenic activity in women than testosterone, were associated with an increased risk of developing non-serous ovarian cancer. Our work demonstrates that sex steroid metabolism is important in the etiology of non-serous ovarian cancers and supports a heterogeneous hormonal etiology across histologic subtypes of ovarian cancer.

KW - androgen metabolites

KW - androgenic activity

KW - endogenous androgens

KW - heterogeneity

KW - nested case–control study

KW - ovarian cancer risk

UR - http://www.scopus.com/inward/record.url?scp=85061594495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061594495&partnerID=8YFLogxK

U2 - 10.1002/ijc.32157

DO - 10.1002/ijc.32157

M3 - Article

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -